

RESEARCH

Open Access



Presence of gastrointestinal symptoms in IgA nephropathy: a cross-sectional study

Jussi T. Pohjonen^{1,2*}, Katri M. Kaukinen^{1,2}, Martti J. Metso², Rakel KK. Nurmi¹, Heini SA. Huhtala³, Ilkka H. Pörsti^{2,4}, Jukka T. Mustonen^{2,4} and Satu M. Mäkelä^{2,4}

Abstract

Background: Gastrointestinal (GI) symptoms are common in end-stage kidney disease. Mounting evidence indicates that the intestine plays an important role in the pathogenesis of IgA nephropathy (IgAN). However, no studies have addressed the obvious question; do IgAN patients suffer from GI symptoms?

Methods: Presence of GI symptoms and health-related quality of life were evaluated using the validated Gastrointestinal Symptom Rating Scale (GSRS) and Psychological General Well-Being (PGWB) questionnaires in 104 patients with kidney biopsy-verified IgAN and in 147 healthy controls. A person was regarded to experience 'increased GI symptoms' if the GSRS score exceeded plus 1 standard deviation of the mean of the corresponding score in the healthy controls.

Results: According to the GSRS total score, the IgAN patients had more GI symptoms than the healthy controls (2.0 vs. 1.7, $p < 0.001$). Female IgAN patients had higher GSRS total score than male patients (2.2 vs. 1.7, $p = 0.001$). More IgAN patients with preserved kidney function ($eGFR > 60 \text{ ml/min/1.73 m}^2$) suffered from increased symptoms of diarrhoea (76 vs. 25%, $p = 0.028$), constipation (81 vs. 19%, $p = 0.046$) and reflux (85 vs. 15%, $p = 0.004$) than did IgAN patients with reduced kidney function ($eGFR < 60 \text{ ml/min/1.73 m}^2$).

Conclusions: IgAN patients and especially female IgAN patients experienced more GI symptoms than healthy controls. More prevalent GI symptoms were already observed before kidney function was clearly reduced. Systematic enquiry of GI symptoms might increase the standard of care among IgAN patients. Moreover, GI symptoms may provide clues for future studies that examine the pathophysiology of IgAN.

Keywords: Chronic kidney disease (CKD), Gastrointestinal Symptom Rating Scale (GSRS), IgA nephropathy (IgAN), Psychological General Well-Being Index (PGWB)

Introduction

IgA nephropathy (IgAN) is the most common primary glomerulonephritis globally and a notable cause of chronic kidney disease (CKD) and kidney failure [1]. Although the pathogenetic mechanisms of IgAN have not been fully determined, there is mounting evidence

that abnormal mucosal immune responses, especially in the intestine, play a role in the disease process [2, 3].

An increased intestinal permeability is present in IgAN [4]. Subclinical small bowel mucosal inflammation has been demonstrated in IgAN patients [5, 6]. The finding of an abundance of intestinal intraepithelial T lymphocytes in IgAN has since been replicated [7]. Associations between IgAN and coeliac disease (CD) are convincing [8–12]. Kidney involvement in inflammatory bowel disease (IBD) is well documented [12–16]. Furthermore, therapy with enteric budesonide targeted at the intestine

*Correspondence: jussi.pohjonen@tuni.fi

¹ Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, FIN-33014 Tampere, Finland

Full list of author information is available at the end of the article



has reportedly reduced the amount of albuminuria in IgAN [17].

Gastrointestinal (GI) symptoms are common in patients with renal insufficiency [18–20]. The prevalence of GI symptoms has mostly been studied in patients with end-stage kidney disease (ESKD) or after kidney transplantation [21–27]. Only few studies have examined the presence of GI symptoms in patients with less advanced CKD [28, 29].

The aim of this study was to evaluate the presence of GI symptoms in IgAN patients with no diagnosed enteropathies and not progressed to ESKD, and to compare the results to those of healthy controls. Health-related quality of life was surveyed simultaneously. We also aimed to identify the predictors of the assumed GI complaints in IgAN.

Materials and methods

Design and study population

A single-centre cross-sectional study was carried out at the Tampere University Hospital (TAUH) and Tampere University, Finland. The TAUH district is an area with a high standard of living and a population of more than 500,000, nearly totally of Caucasian origin. About one hundred kidney biopsies are taken in TAUH annually due to clinical indications [30]. A total of 533 patients with biopsy-proven IgAN diagnosed between 1980 to 2018 were included. The definition of IgAN was based on clinical details and on the presence of glomerular IgA as the sole or predominant immunofluorescence finding [31].

The clinical histories of the 533 IgAN patients were collected from the medical records. Based on the following predefined exclusion criteria, 327 patients were excluded: death ($n=51$), progression to ESKD (defined as estimated glomerular filtration rate (eGFR) <15 ml/min/1.73m², initiation of maintenance dialysis or kidney transplantation, $n=64$), age under 18 or over 80 at recruitment ($n=78$), known chronic enteropathy (CD or IBD, $n=16$) [12], moving to another hospital district ($n=79$), or other obvious reason for exclusion (major GI surgery performed, missing contact information, short life-expectancy for any reason, or a labile mental disorder, $n=39$). Study questionnaires were posted to the remaining 206 patients in August 2019. The patients were requested to return the questionnaires and the signed informed consent forms within one month. For those who did not return the forms, we verified the contact information and posted the forms in a similar manner once again.

The healthy controls were selected from a group originally comprising 160 people, who had participated in our earlier study [32]. As we restricted them to the same age (18 to 80) as the IgAN patients, the remaining number of

available healthy controls was 147. The group was used for the comparison of gastrointestinal symptoms and quality of life. These subjects had no known intestinal diseases at the time of participation, nor did they have first-degree relatives with CD. No laboratory testing had been performed, thus no information, for example on actual kidney function, was available.

Study questionnaires

For the systematic evaluation of current GI symptoms, all participants completed the self-administered, structured, and well-validated Gastrointestinal Symptom Rating Scale (GSRS) questionnaire [33–35]. The questionnaire evaluates five sub-dimensions of gastrointestinal symptoms: indigestion, diarrhoea, abdominal pain, reflux, and constipation. It comprises altogether 15 separate items. The scoring goes from 1 to 7 points, where 1 point signifies no symptoms, and 7 points signifies the most severe symptoms. The values for each of the five sub-dimension scores were calculated as a mean of the respective items and the total GSRS score as a mean of all 15 items. A person was deemed to suffer from ‘increased GI symptoms’ if the total GSRS score exceeded plus 1 standard deviation (SD) of the mean of the total score in the healthy controls [32]. The same principle was applied to the GSRS sub-scores: ‘increased symptoms’ were taken to be present if an individual’s score exceeded plus 1 SD of the mean of the corresponding sub-score in the healthy controls.

All participants also completed the self-administered, validated questionnaire to measure health-related quality of life, the Psychological General Well-Being (PGWB) questionnaire [36–38]. The survey consists of 22 separate items covering six different sub-dimensions: anxiety, depression, wellbeing, self-control, general health, and vitality. The scoring goes from 1 to 6 points, higher score indicating better quality of life. The sub-dimension scores are calculated as a sum of the items in each sub-dimension and the total PGWB score as a sum of all 22 items.

For the IgAN patients, in addition, information about co-morbidities, and current height and weight was elicited. Tobacco and alcohol consumption were evaluated with standardized tools: The Fagerström Test for Nicotine Dependence and the Alcohol Use Disorders Identification Test (AUDIT-C) questionnaire respectively [39, 40].

Clinical data

The clinical data for IgAN patients was collected retrospectively from the medical records between 2019 and 2020. We collected data on medications used during the preceding year (antibiotics as courses of treatment), information on possible abdominal surgery and visits and

treatments at the nephrological outpatient clinic or ward. Follow-up at the nephrological unit was deemed active if a patient had made one visit during the preceding year and a control visit had been planned. Laboratory test results regarding kidney function were collected for no later than one year preceding the study recruitment.

Kidney function was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation [41]. $eGFR > 60 \text{ ml/min/1.73m}^2$ was regarded as preserved kidney function. Body mass index (BMI) was calculated according to numbers reported in the study questionnaire, by dividing the weight (kilograms) by the square of height (metres).

Statistical methods

The data are presented as medians and interquartile ranges (IQR) for most of the continuous variables and as percentages for the categorical variables. If a patient failed to answer one or two items in the GSRS or PGWB questionnaires, the missing answer was replaced by the mean value of the other scores for the same subject. If more than two answers were missing, the questionnaire was rejected.

The groups were compared using the Chi-square test, Fisher's exact test or the Mann–Whitney *U*-test, as appropriate. Binary logistic regression analysis was applied to identify factors for increased GI symptoms. Three covariates were used to avoid overfitting the model. The associations are presented as odds ratios (OR) with 95% confidence intervals (CI).

All tests were two-sided, and *p*-values less than 0.05 were considered statistically significant. All statistical testing was performed using SPSS version 27.0 (IBM SPSS, NY, USA).

Ethical considerations

The study protocol was approved by the Ethics Committee of the Tampere University Hospital (R18215). All study participants provided written informed consent.

Results

Clinical characteristics

Altogether 104 IgAN patients participated in the study. Median age was 55 years, 54% were males and median BMI was 29. Median time from the kidney biopsy was 11 years. Information about current kidney function was available from 82 patients and was preserved ($eGFR > 60 \text{ ml/min/1.73m}^2$) in 56% of them. Sixty-three

per cent of the patients with preserved kidney function were females.

Female IgAN patients were younger, their BMI was slightly lower, they had better kidney function, and they more often reported concomitant thyroid diseases than male patients. IgAN patients' detailed characteristics are presented sex-based in Table 1.

There was a clear female preponderance (72%) among the healthy controls. The median age of the healthy controls was 54 years (42–68), so the groups did not differ in age ($p = 0.979$). Women were younger than men in the healthy controls, too ($p < 0.001$).

Gastrointestinal symptoms and health-related quality of life

Compared to healthy controls, patients with IgAN reported more GI symptoms as determined by higher GSRS total score (2.0 vs. 1.7, $p < 0.001$). The GSRS sub-scores for diarrhoea, indigestion, reflux, and abdominal pain were also significantly higher among the patients than in controls (Table 2). Female IgAN patients had higher GSRS total score and sub-scores of indigestion, constipation and abdominal pain than male IgAN patients (Table 3). Total GSRS score did not differ between male IgAN patients and male controls (1.7 vs. 1.7, $p = 0.411$), but male IgAN patients had a higher sub-score for diarrhoea (1.7 vs. 1.3, $p = 0.025$). GSRS questionnaires were rejected for two participants among the healthy controls, and for one IgAN patient due to insufficient completion of the questionnaire.

PGWB total score as well as general health and vitality sub-scores were significantly inferior in patients with IgAN than those in healthy controls (Table 2). PGWB scores did not differ between female and male IgAN patients (Table 3). PGWB questionnaires of five participants among the healthy controls and one IgAN patient were rejected due to incomplete response to the questionnaire.

Prevalence of increased GI symptoms was more common in IgAN patients than among healthy controls (Fig. 1) and significantly more so when female IgAN patients were compared with healthy women (Fig. 2). No differences were observed in the prevalence of increased GI symptoms between male IgAN patients and healthy males (data not shown). IgAN patients with preserved kidney function reported increased GI symptoms more often than IgAN patients with reduced kidney function in the GSRS sub-scores for diarrhoea (76 vs. 25%, $p = 0.028$), constipation (81 vs. 19%, $p = 0.046$) and reflux (85 vs. 15%, $p = 0.004$). In a multivariable logistic regression analysis of risk factors for increased

Table 1 Clinical characteristics of the 104 IgA nephropathy patients. Values are medians (interquartile range) unless otherwise indicated

Patient characteristics	Females	Males	p-value
Number of subjects	48	56	
Current age, years	52 (37–58)	59 (51–70)	< 0.001
Current body mass index, kg/m ²	27 (24–32)	29 (27–33)	0.048
Current smoker, %	19	7	0.135
Risky alcohol use ^a , %	23	29	0.654
Coexisting conditions, %			
Hypertension	40	63	0.030
Diabetes	8	16	0.373
Asthma or chronic obstructive pulmonary disease	17	14	0.790
Sleep apnoea	10	10	1.000
Rheumatic disease	13	7	0.507
Thyroid disease	21	4	0.011
Cancer; active or treated	6	2	0.333
Depression	10	5	0.334
Medication during the year before the study, %			
Blood pressure lowering	69	84	0.101
Lipid lowering	31	43	0.310
Glucose lowering	9	13	0.750
Immunosuppressive	8	4	0.299
Antibiotics	50	43	0.555
Proton pump inhibitor	23	23	1.000
Active follow-up at the nephrological unit, %	21	23	0.816
Time since diagnostic kidney biopsy, years	10 (4–20)	11 (6–20)	0.150
Current kidney function, data available from 41 female and 41 male patients			
Estimated glomerular filtration rate (eGFR), ml/min/1.73m ²	78 (54–93)	54 (36–68)	< 0.001
eGFR < 60 ml/min/1.73m ² , %	29	59	0.014

^a For women 5 or more points, for men 6 or more points in the Alcohol Use Disorders Identification Test (AUDIT–C)

GI symptoms among IgAN patients, female sex was positively and PGWB total score negatively associated with the higher points in the GSRS total score (Table 4).

Discussion

IgAN patients had higher prevalence of GI symptoms than did healthy subjects, and especially female patients with IgAN were more symptomatic than males. An interesting finding was female IgAN patients experiencing increased GI symptoms more often compared to healthy women. Even though male IgAN patients had the same GSRS total score as healthy males, they had higher scores regarding diarrhoea. Interestingly, IgAN patients with preserved kidney function reported more often increased symptoms of diarrhoea, constipation, and reflux than patients with reduced kidney function. IgAN patients experienced poorer health-related quality of life than healthy controls, especially regarding general health and

vitality. Furthermore, poorer quality of life associated with increased GI symptoms.

GI symptoms have not previously been evaluated in such a well-defined kidney disease population as in the present study. The fact that diagnosed intestinal diseases were excluded from the current study diminishes the possibility of the findings being biased by the presence of concomitant IBD or CD. In an earlier study where variable diseases had led to CKD stage 4 but dialysis was not yet required (eGFR < 25 ml/min/1.73m²), the median of the GSRS total score was 1.84 and the median for the sub-scores were as follows: diarrhoea 1.67, indigestion 2.12, constipation 1.67, reflux 1.00 and abdominal pain 1.50 [21]. In the present study, all sub-scores, and thus also the total score, were at least as high among the IgAN patients. The GSRS total score of 2.0 (1.5–2.7) in IgAN patients in our study was close to the score of the peritoneal dialysis (PD) patients in the aforementioned study (2.07, 1.48–3.08) [21]. PD patients are well known to suffer from excess of GI symptoms [25, 26, 42].

Table 2 Comparison of GSRS and PGWB scores (median and interquartile range) between IgA nephropathy (IgAN) patients and healthy controls

	IgAN patients	Healthy controls	p-value
GSRS, number of subjects ^a	103	145	
Total score	2.0 (1.5–2.7)	1.7 (1.4–2.2)	< 0.001
Diarrhoea	1.7 (1.0–2.7)	1.3 (1.0–2.0)	< 0.001
Indigestion	2.5 (2.0–3.3)	2.3 (1.6–2.8)	0.020
Constipation	1.7 (1.0–2.3)	1.3 (1.0–2.0)	0.093
Reflux	1.5 (1.0–2.5)	1.0 (1.0–1.5)	< 0.001
Abdominal pain	1.7 (1.3–2.3)	1.7 (1.0–2.0)	0.006
PGWB, number of subjects ^b	103	142	
Total score	104 (95–113)	109 (101–115)	0.015
Anxiety	25 (22–27)	25 (23–27)	0.292
Depression	17 (16–18)	17 (16–18)	0.656
Wellbeing	17 (15–19)	18 (16–19)	0.585
Self-control	16 (15–17)	16 (14–17)	0.243
General health	13 (10–14)	15 (13–16)	< 0.001
Vitality	17 (15–19)	19 (17–21)	< 0.001

GSRS Gastrointestinal Symptom Rating Scale, PGWB Psychological General Well-being Index

^a GSRS rejected for two healthy controls and one IgAN patient due to incomplete questionnaire

^b PGWB disqualified for five healthy controls and one IgAN patient due to incomplete questionnaire

Table 3 Sex-based comparison of GSRS and PGWB scores (median and interquartile range) in IgA nephropathy patients

	Female	Male	p-value
GSRS, number of subjects ^a	47	56	
Total score	2.2 (1.8–2.9)	1.7 (1.5–2.3)	0.001
Diarrhoea	1.7 (1.0–3.7)	1.7 (1.3–2.3)	0.767
Indigestion	3.0 (2.3–3.5)	2.3 (1.8–3.0)	0.005
Constipation	2.3 (1.3–3.7)	1.3 (1.0–2.0)	< 0.001
Reflux	1.8 (1.0–3.0)	1.5 (1.0–2.0)	0.178
Abdominal pain	2.2 (1.7–2.7)	1.7 (1.3–2.0)	< 0.001
PGWB, number of subjects ^b	48	55	
Total score	103 (90–112)	105 (98–114)	0.217
Anxiety	25 (20–27)	25 (22–27)	0.145
Depression	17 (15–18)	17 (16–18)	0.261
Wellbeing	18 (14–19)	17 (16–19)	0.576
Self-control	16 (14–17)	16 (15–17)	0.218
General health	13 (10–15)	13 (11–14)	0.223
Vitality	17 (15–20)	17 (16–19)	0.632



GSRS Gastrointestinal Symptom Rating Scale, PGWB Psychological General Well-Being Index

^a GSRS rejected for one IgAN patient due to incomplete questionnaire

^b PGWB disqualified for one IgAN patient due to incomplete questionnaire

Why did female IgAN patients suffer more often from GI symptoms than male IgAN patients? In general, irritable bowel syndrome (IBS) is more common in women than in men [43]. IBS was also more common among Turkish female than male dialysis patients [44]. Yet, no differences were found in the presence of GI symptoms between sexes in two studies evaluating ESKD patients [21, 42]. Among Australian kidney transplant patients, women again experienced more GI symptoms [27]. Thirty-nine percent of those patients had glomerulonephritis as the primary kidney disease. The sex disparity was speculated to be explained by e.g. hormonal levels, composition of gastrointestinal microbiota, and the finding of women reporting more GI symptoms to health care professionals when compared with men [27]. One explanation could be abdominal discomfort and pain related to the menstrual cycle in fertile-aged women. Still, despite any of the reasons speculated above, female controls in the current study experienced significantly less GI symptoms compared to female IgAN patients.

The present study was unique in focusing on patients with fairly well preserved kidney function; over 50% of the patients had eGFR above 60 ml/min/1.73m². Conventionally, the presence of GI symptoms has been studied in patients who have progressed to ESKD [25, 42]. To the best of our knowledge, only one study has so far evaluated the presence of GI symptoms with the GSRS questionnaire in CKD patients not on dialysis and before transplantation [21]. The other two studies that evaluated the presence of GI symptoms in patients who had not progressed to ESKD used a self-administered patient symptom form, which elicited GI symptoms originally presented in the Modification of Diet in Renal Disease (MDRD) study [28, 29] 'Abdominal bloating or gas' were among the most commonly reported symptoms in the MDRD study [28]. Moreover, the GI symptoms were reported to emerge long before ESKD, but still only after eGFR had fallen below 45 ml/min/1.73m² [28]. In the latter study, GI symptoms became more common as kidney function declined, the one exception being 'abdominal bloating or gas', which was equally common and frequently experienced with preserved kidney function [29]. So, why did IgAN patients with better kidney function report increased symptoms of diarrhoea, constipation, and reflux more often than those with reduced kidney function in our study? Etiology of GI symptoms is multifactorial, e.g. higher age diminishes the prevalence of IBS symptoms whereas increased IP and mucosal inflammation likely activate visceral pain in some IBS patients [43, 45]. If GI tract plays a role in the pathogenesis of IgAN, the possible mechanisms might differ between the early and the advanced stages of the disease.



A well-defined and -sized group of patients with a definite diagnosis of IgAN is the strength of the current study. The male/female rate was similar as has been previously reported in IgAN and other glomerular diseases [30]. Exclusion of previously diagnosed intestinal diseases enabled us to focus on the study hypothesis of IgAN patients experiencing GI symptoms without clinically evident enteropathies. Information about kidney function was available in most cases and was most often

regarded as normal, making our study population unique in abandoning the conventional idea of GI symptoms becoming prevalent first in advanced CKD.

Our study has some limitations. There was no control group with primary glomerulonephritides, which leaves it uncertain whether the patients experienced an excess of GI symptoms due to kidney disease in general or were the symptoms related with IgAN. The study was carried out in one centre, thus weakening the generalisability

Table 4 Univariate and multivariable logistic regression analyses of risk factors for increased gastrointestinal symptoms among 103 IgA nephropathy patients

	Univariate			Multivariable		
	OR	95% CI	p-value	OR	95% CI	p-value
Female sex	3.30	1.38–7.93	0.007	2.80	1.08–7.29	0.035
PGWB total score	0.96	0.93–0.99	0.008	0.96	0.93–1.00	0.026
Age	0.98	0.95–1.01	0.202	1.00	0.97–1.03	0.958
Antibiotic courses	2.25	0.96–5.26	0.063			
Smoking	3.03	0.93–9.91	0.066			
Risky alcohol use ^a	2.24	0.90–5.59	0.084			
Thyroid disease	3.05	0.86–10.85	0.086			
PPI medication	1.85	0.72–4.78	0.204			
eGFR > 60ml/min/1.73m ²	1.80	0.67–4.87	0.247			
Body mass index	0.97	0.90–1.04	0.359			

PGWB Psychological General Well-being Index, eGFR estimated glomerular filtration rate, PPI proton pump inhibitor

^a For women 5 or more points, for men 6 or more points in the Alcohol Use Disorders Identification Test (AUDIT-C)

of the results. The two study groups had answered the questionnaires years apart. Yet, the results of the healthy controls were consistent with the controls in previous studies [21, 34]. The kidney function was regarded as current, despite the laboratory tests had in many cases been taken months before the study participation, and the information was not available for one fifth of the IgAN patients at all. Taking the most often slowly progressive or stable nature of IgAN into account, it's unlikely that a significant proportion of the study patients would have had a rapidly progressive disease. Symptomatic patients might have participated more eagerly than asymptomatic patients. This too seems unlikely, as more than one half of the participating IgAN patients were men and their GSRS total score was comparable to that in the healthy controls. Female IgAN patients reported more often thyroid diseases than males, which might explain some of the GI symptoms experienced by females. Thyroid dysfunction in general is more prevalent in women compared to men [46]. Usually GI symptoms in thyroid diseases resolve with treatment [47].

Conclusions

IgAN patients and especially female IgAN patients suffered from excess GI symptoms even though kidney function was well preserved, and no enteropathies had been diagnosed. Male IgAN patients had also higher scores regarding the presence of diarrhoea than male controls. More prevalent GI symptoms were associated with poorer quality of life, a finding consistent with previous studies [21, 23, 27]. The present findings suggest that

routine eliciting of IgAN patients' GI symptoms would be an appropriate clinical practice. Even though GI symptoms have multifactorial explanations and are not related to IgAN only, perhaps symptoms like presence of loose stools could guide future studies in revealing the complex pathophysiology of IgAN.

Abbreviations

BMI: body mass index; CD: coeliac disease; CI: confidence interval; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; ESKD: end-stage kidney disease; GI: gastrointestinal; GSRS: Gastrointestinal Symptom Rating Scale; IBD: inflammatory bowel disease; IBS: irritable bowel syndrome; IgAN: IgA nephropathy; IP: intestinal permeability; IQR: interquartile range; PD: peritoneal dialysis; PGWB: Psychological General Well-Being Index.

Acknowledgements

The valuable work of Dr. Ole Wirta M.D, Ph.D. is greatly appreciated.

Authors' contributions

All authors participated in the design of the study. J.P. and M.M. collected the data. J.P. and H.H. analysed and interpreted the data. J.P. and K.K. drafted the article. All authors provided intellectual content of critical importance to the study, and read, revised, and approved the final manuscript.

Funding

This study was supported by the Academy of Finland, the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (9AA026, 9AA052, 9AB025, 9T039, MK303), the Finnish Coeliac Society, the Finnish Society of Nephrology, and the Sigrid Jusélius Foundation. The funding sources were not involved in the study design; in the collection, analysis, and interpretation of the data; in the writing of the report; or in the decision to submit the article for publication.

Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study protocol complied with the Helsinki Declaration standards and was approved by the Ethics Committee of the Tampere University Hospital (R18215). All study participants provided written informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, FIN-33014 Tampere, Finland. ²Department of Internal Medicine, Tampere University Hospital, Tampere, Finland. ³Faculty of Social Sciences, Tampere University, Tampere, Finland. ⁴Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

Received: 11 May 2022 Accepted: 28 November 2022

Published online: 08 December 2022

References

- Rodrigues JC, Haas M, Reich HN. IgA nephropathy. *Clin J Am Soc Nephrol*. 2017;12(4):677–86.
- Coppo R. The intestine-renal connection in IgA nephropathy. *Nephrol Dial Transplant*. 2015;30(3):360–6.
- Floege J, Feehally J. The mucosa-kidney axis in IgA nephropathy. *Nat Rev Nephrol*. 2016;12(3):147–56.
- Rostoker G, Wirquin V, Terzidis H, et al. Mucosal Immun Prim Glomerulonephritis *Nephron*. 1993;63(3):286–90.
- Rantala I, Collin P, Holm K, Kainulainen H, Mustonen J, Mäki M. Small bowel T cells, HLA class II antigen DR, and GroEL stress protein in IgA nephropathy. *Kidney Int*. 1999;55(6):2274–80.
- Honkanen T, Mustonen J, Kainulainen H, et al. Small bowel cyclooxygenase 2 (COX-2) expression in patients with IgA nephropathy. *Kidney Int*. 2005;67(6):2187–95.
- Rostoker G, Delchier JC, Chaumette MT. Increased intestinal intra-epithelial T lymphocytes in primary glomerulonephritis. A role of oral tolerance breakdown in the pathophysiology of human primary glomerulonephritides? *Nephrol Dial Transplant*. 2001;16(3):513–7.
- Collin P, Syrjänen J, Partanen J, Pasternack A, Kaukinen K, Mustonen J. Celiac disease and HLA DQ in patients with IgA nephropathy. *Am J Gastroenterol*. 2002;97(10):2572–6.
- Pierucci A, Fofi C, Bartoli B, et al. Antiendomysial antibodies in Berger's disease. *Am J Kidney Dis*. 2002;39(6):1176–82.
- Welander A, Sundelin B, Fored M, Ludvigsson JF. Increased risk of IgA nephropathy among individuals with celiac disease. *J Clin Gastroenterol*. 2013;47(8):678–83.
- Nurmi R, Metso M, Pörsti I, et al. Celiac disease or positive tissue transglutaminase antibodies in patients undergoing renal biopsies. *Dig Liver Dis*. 2018;50(1):27–31.
- Nurmi R, Pohjonen J, Metso M, et al. Prevalence of Inflammatory Bowel Disease and Celiac Disease in Patients with IgA Nephropathy over Time. *Nephron*. 2021;145(1):78–84.
- Ambruzs JM, Walker PD, Larsen CP. The histopathologic spectrum of kidney biopsies in patients with inflammatory bowel disease. *Clin J Am Soc Nephrol*. 2014;9(2):265–70.
- Corica D, Romano C. Renal involvement in inflammatory bowel diseases. *J Crohns Colitis*. 2015;10(2):1–10.
- Pohjonen J, Nurmi R, Metso M, et al. Inflammatory bowel disease in patients undergoing renal biopsies. *Clin Kidney J*. 2019;12(5):645–51.
- Rehnberg J, Symreng A, Ludvigsson JF, Emilsson L. Inflammatory Bowel Disease Is More Common in Patients with IgA Nephropathy and Predicts Progression of ESKD: A Swedish Population-Based Cohort Study. *J Am Soc Nephrol*. 2021 Feb;32(2):411–23.
- Fellström BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. *The Lancet*. 2017;389(10084):2117–27.
- Shirazian S, Radhakrishnan J. Gastrointestinal disorders and renal failure: Exploring the connection. *Nat Rev Nephrol*. 2010;6(8):480–92.
- Costa-Moreira P, Vilas-Boas F, Teixeira Fraga A, Macedo G. Particular aspects of gastroenterological disorders in chronic kidney disease and end-stage renal disease patients: a clinically focused review. *Scand J Gastroenterol*. 2020;55(2):129–38.
- Sumida K, Yamagata K, Kovesdy CP. Constipation in CKD. *Kidney Int Rep*. 2020;5(2):121–34.
- Strid H, Simrén M, Johansson AC, Svedlund J, Samuelsson O, Björnsson ES. The prevalence of gastrointestinal symptoms in patients with chronic renal failure is increased and associated with impaired psychological general well-being. *Nephrol Dial Transplant*. 2002;17(8):1434–9.
- Cano AE, Neil AK, Kang JY, et al. Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis. *Am J Gastroenterol*. 2007;102(9):1990–7.
- Ponticelli C, Colombo D, Novara M, Basilisco G. Gastrointestinal symptoms impair quality of life in Italian renal transplant recipients but are under-recognized by physicians. *Transpl Int*. 2010;23(11):1126–34.
- Dong R, Guo ZY, Ding JR, Zhou YY, Wu H. Gastrointestinal symptoms: A comparison between patients undergoing peritoneal dialysis and hemodialysis. *World J Gastroenterol*. 2014;20(32):11370–5.
- Zuvela J, Trimmingham C, le Leu R, et al. Gastrointestinal symptoms in patients receiving dialysis: A systematic review. *Nephrology*. 2018;23(8):718–27.
- Kosmadakis G, Albaret J, da Costa Correia E, Somda F, Aguilera D. Gastrointestinal Disorders in Peritoneal Dialysis Patients. *Am J Nephrol*. 2018;48(5):319–25.
- Chan S, Cao C, Pascoe EM, et al. Patient-Reported Gastrointestinal Symptoms and the Association With Quality of Life Following Kidney Transplantation. *Kidney Int Rep*. 2021;6(1):138–45.
- Rocco M, Gassman JJ, Wang S, Kaplan RM. Cross-Sectional Study of Quality of Life and Symptoms in Chronic Renal Disease Patients: The Modification of Diet in Renal Disease Study. *Am J Kidney Dis*. 1997;29(6):888–96.
- Zhang X, Bansal N, Go AS, Hsu CY. Gastrointestinal symptoms, inflammation and hypoalbuminemia in chronic kidney disease patients: A cross-sectional study. *BMC Nephrol*. 2015;16(1):1–8.
- Wirta O, Mustonen J, Helin H, Pasternack A. Incidence of biopsy-proven glomerulonephritis. *Nephrol Dial Transplant*. 2008;23(1):193–200.
- Mustonen J, Pasternack A, Helin H, Nikkilä M. Clinicopathologic correlations in a series of 143 patients with IgA glomerulonephritis. *Am J Nephrol*. 1985;5(3):150–7.
- Laurikka P, Salmi T, Collin P, Huhtala H, Mäki M, Kaukinen K, et al. Gastrointestinal symptoms in celiac disease patients on a long-term gluten-free diet. *Nutrients*. 2016;8(7):1–11.
- Dimenäs E, Glise H, Hallerbäck B, et al. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. *Scand J Gastroenterol*. 1995;30(11):1046–52.
- Dimenäs E, Carlsson G, Glise H, Israelsson B, Wiklund I. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. *Scand J Gastroenterol Suppl*. 1996;31(221):8–13.
- Kleinman L, Kilburg A, Machnicki G, Faull R, Walker R, Prasad R, et al. Using GI-specific patient outcome measures in renal transplant patients: Validation of the GSRS and GIQLI. *Qual Life Res*. 2006;15(7):1223–32.
- Viljamaa M, Collin P, Huhtala H, Sievänen H, Mäki M, Kaukinen K. Is coeliac disease screening in risk groups justified? A fourteen-year follow-up with special focus on compliance and quality of life. *Aliment Pharmacol Ther*. 2005;22(4):317–24.
- Roos S, Kärner A, Hallert C. Psychological well-being of adult coeliac patients treated for 10 years. *Dig Liver Dis*. 2006;38(3):177–80.
- Paarlahti P, Kurppa K, Ukkola A, et al. Predictors of persistent symptoms and reduced quality of life in treated coeliac disease patients: A large cross-sectional study. *BMC Gastroenterol*. 2013;13:75.
- Fagerstrom KO, Schneider NG. Measuring nicotine dependence: A review of the Fagerstrom Tolerance Questionnaire. *J Behav Med*. 1989;12(2):159–82.

40. Higgins-Biddle JC, Babor TF. A review of the Alcohol Use Disorders Identification Test (AUDIT), AUDIT-C, and USAUDIT for screening in the United States: Past issues and future directions. *Am J Drug Alcohol Abuse*. 2018;44(6):578–86.
41. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604–12.
42. Yi C, Wang X, Ye H, Lin J, Yang X. Patient-reported gastrointestinal symptoms in patients with peritoneal dialysis: the prevalence, influence factors and association with quality of life. *BMC Nephrol*. 2022;23(1):99.
43. Chang L, Toner BB, Fukudo S, et al. Gender, Age, Society, Culture, and the Patient's Perspective in the Functional Gastrointestinal Disorders. *Gastroenterology*. 2006;130(5):1435–46.
44. Kahvecioglu S, Akdag I, Kiyici M, et al. High prevalence of irritable bowel syndrome and upper gastrointestinal symptoms in patients with chronic renal failure. *J Nephrol*. 2005;18(1):61–6.
45. Camilleri M, Lasch K, Zhou W. Irritable Bowel Syndrome: Methods, Mechanisms, and Pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. *Am J Physiol Gastrointest Liver Physiol*. 2012;303(7):775–85.
46. Madariaga AG, Santos Palacios S, Guillén-Grima F, Galofré JC. The incidence and prevalence of thyroid dysfunction in Europe: A meta-analysis. *J Clin Endocrinol Metab*. 2014;99(3):923–31.
47. Ebert EC. The thyroid and the gut. *J Clin Gastroenterol*. 2010;44(6):402–6.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

